Clinical trials: Candidemia
Bacteremia, Candidemia
Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
The purpose of this study is to assess the effectiveness of RaPID/BSI by testing its performance compared to blood cultures collected prospectively from consented subjects.
- Trial name
- NCT04147975
- Testing
- RaPID/BSI Test
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- HelixBind, Inc.
Candidemia
Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)
The purpose of this study is to validate clinical performance (i.e. estimated sensitivity and specificity) of the T2 Candida test on the T2 DX Instrument compared to blood culture results and/or known Candida positive status of…
- Trial name
- direcT2 (NCT01752166)
- Where
- 8 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- T2 Biosystems
Candidiasis, Fungemia
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
The purpose of this study is to gather information on the use of anidulafungin for the treatment of serious Candida infection. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug…
- Trial name
- NCT00805740
- Testing
- Active anidulafungin, Active Caspofungin
- Where
- 18 sites in United States, Belgium and 7 more
- Volunteers
- 41 people
- Sponsor
- Pfizer
Candidemia, Invasive Candidiasis
CRITIC - Treatment of Candidemia and Invasive Candidiasis
Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
- Trial name
- CRITIC (NCT00670657)
- Testing
- AmBisome
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Invasive Candidiasis
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients.
- Trial name
- ICE (NCT00689338)
- Testing
- Anidulafungin, Fluconazole, Voriconazole
- Where
- 61 sites in Austria, Belgium and 17 more
- Volunteers
- 216 people
- Sponsor
- Pfizer
Candidiasis
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or…
- Trial name
- NCT00106288
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 37 sites in United States, Canada
- Volunteers
- 637 people
- Sponsor
- Astellas Pharma Inc
Candidiasis, Invasive, Candidemia
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis including candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous…
- Trial name
- MARIO (NCT05178862)
- Testing
- SCY-078, Fluconazole, Echinocandin
- Where
- 101 sites in United States, Belgium and 11 more
- Volunteers
- 68 people
- Sponsor
- Scynexis, Inc.